Navigation Links
Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Date:12/13/2007

ids and HbA1c and, in the BLOOM-DM trial, other indicators of glycemic control will also be evaluated. In both of these additional studies, all patients will receive echocardiograms at baseline, at month 6, and at the end of the study to assess heart valve function over time. In contrast to the ongoing BLOOM trial, however, there will be no independent monitoring by an Echocardiographic Safety Monitoring Board. The complete lorcaserin Phase 3 pivotal program is planned to enroll a total of approximately 7,000 patients in these three trials. In addition to the planned pivotal trial program, several additional small studies, such as drug interaction and abuse potential studies, will be conducted.

"As we continue advancing our lorcaserin clinical program, we are looking forward to March 2008 when we expect the BLOOM Echocardiographic Safety Monitoring Board's review of echocardiograms for patients completing 12 months of treatment. We will continue to work with the FDA as we implement the final non-pivotal trial elements of the complete Phase 3 program," stated William R. Shanahan, M.D., Arena's Vice President and Chief Medical Officer.

An earlier estimate of the total external clinical costs of the Phase 3 trial program was updated from approximately $125 million to approximately $160 million. The increased estimate is primarily due to the increased number of patients Arena plans to enroll, and to Arena's initiative to expand the echocardiographic monitoring program by including patients with FDA-defined valvulopathy in the BLOSSOM and BLOOM-DM trials.

About Lorcaserin

Lorcaserin, Arena's internally discovered oral drug candidate for the treatment of obesity, is in an ongoing Phase 3 program. The compound stimulates the 5-HT2C serotonin receptor, located in the hypothalamus, an area of the brain associated with the control of satiety and metabolism. Results from Phase 2 studies demonstrated that treatment with lorcaserin produced highly sta
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... , April 23, 2015 Prospects ...   Report Details   We predict ... value of $101.3 billion in 2015 and will grow at ... in the healthcare sectors around the world and increasing functional ... growth factors in the global healthcare packaging market. ...
(Date:4/23/2015)... 2015  Metanome, Inc., an industry leader in ... changed its name to Diversigen, Inc.  The name ... single commercial source for the myriad of services ... diverse opportunities of the microbiome.  From the wide ... including those that are difficult to handle, such ...
(Date:4/23/2015)... ReliantHeart's HeartAssist5® Ventricular Assist Device (VAD) precisely measure ... in real time, and this data is uploaded to ... Machine to Machine (M2M) communications for the Internet of ... can be monitored by a patient’s clinician 24/7, ... a minimum threshold, the patient can be notified immediately. ...
(Date:4/22/2015)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ) today reported ... For the first quarter ended March 31, 2015, ... or $0.08 per share, compared to a net loss ... same period in 2014. As of March 31, 2015, ... interest receivable of $226.1 million. Revenues for ...
Breaking Biology Technology:Healthcare Packaging Market Forecast 2015-2025 2Healthcare Packaging Market Forecast 2015-2025 3Healthcare Packaging Market Forecast 2015-2025 4Healthcare Packaging Market Forecast 2015-2025 5Healthcare Packaging Market Forecast 2015-2025 6Healthcare Packaging Market Forecast 2015-2025 7Healthcare Packaging Market Forecast 2015-2025 8Healthcare Packaging Market Forecast 2015-2025 9Healthcare Packaging Market Forecast 2015-2025 10Metanome Announces Corporate Name Change to Diversigen 2Sangamo BioSciences Reports First Quarter 2015 Financial Results 2Sangamo BioSciences Reports First Quarter 2015 Financial Results 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 4Sangamo BioSciences Reports First Quarter 2015 Financial Results 5Sangamo BioSciences Reports First Quarter 2015 Financial Results 6Sangamo BioSciences Reports First Quarter 2015 Financial Results 7Sangamo BioSciences Reports First Quarter 2015 Financial Results 8
... JCA-Mauvernay Award, LAUSANNE, Switzerland, October 29 ... specialist that,focuses on serious medical conditions and ... Mano with the 2008 JCA-Mauvernay,Award for their ... oncology.,The Awards were presented during the General ...
... Proximal Anastomosis System Received 510(k) Clearance from ... Drug Administration (FDA) -, - Development Progress Triggered $1M Milestone Payment from ... - Conference Call Today at 4:30 p.m. Eastern Time -, REDWOOD ... financial results and corporate progress,for its fiscal 2009 first quarter ended September ...
... COLUMBIA, Canada, Oct. 28 InNexus,Biotechnology Inc., (OTC ... a drug development company commercializing the next,generation of ... technology, announces that Jeff Morhet, CEO and Chairman, ... on October 30, 2008., Mr. Morhet,s thirty-minute ...
Cached Biology Technology:Japanese Cancer Association and Debiopharm Honour Japanese Research 2Japanese Cancer Association and Debiopharm Honour Japanese Research 3Cardica Announces Fiscal 2009 First Quarter Financial Results 2Cardica Announces Fiscal 2009 First Quarter Financial Results 3Cardica Announces Fiscal 2009 First Quarter Financial Results 4Cardica Announces Fiscal 2009 First Quarter Financial Results 5Cardica Announces Fiscal 2009 First Quarter Financial Results 6InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum 2
(Date:3/23/2015)... SoundView Technology Group issues a new research update following the ... wallet. SoundView was one of the selected user groups to provide ... in multiple scenarios and outlets. Soundview shares ... both debit and credit card payments.  Soundview ... meets their plans in 2015, it would push our IV ...
(Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
(Date:3/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces its ... of the products featured in 2015 "I Want That" ... PM EST on the DIY Network.   ... Vegas , site of the 2015 International CES ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... Researchers at UCLA,s Henry Samueli School of Engineering and ... butanol often proposed as a "greener" fuel alternative ... significantly higher than those achieved using current production methods. ... the journal Applied and Environmental Microbiology , mark ...
... MIAMI March 17, 2010 -- University of Miami (UM) ... and colleagues developed a new tool to monitor coral reef ... better assess how climate change and other ecological threats impact ... During a March 2009 experiment at Cayo Enrique Reef ...
... time to quickly swipe your pager or cell phone three times, ... of the bacteria. And a simple tissue moistened with saline would ... single swipe of a ,dirty, phone you,d be better off ... a recently published research study that appeared online in PubMed ...
Cached Biology News:UCLA researchers engineer E. coli to produce record-setting amounts of alternative fuel 2Study provides new tool to monitor coral reef 'vital signs' 2Bacterial wipes research study 2
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
Biology Products: